Affordable Diabetes and Weight Loss Drugs Coming Soon

New Delhi: Millions of Indians struggling with diabetes and obesity may soon get some relief as affordable versions of semaglutide, the key ingredient in Ozempic and Wegovy, are set to hit the market after March 2026. Experts say this could make treatment accessible for a much larger population, especially in price-sensitive areas.

Pharmaceutical companies in India are gearing up for the launch of these generic drugs. Dr. Reddy’s Laboratories has already received approval from the Drug Controller General of India (DCGI) and plans to manufacture 12 million semaglutide pens in the first year. Sun Pharma will launch its generic under the brand name “Noveltreat”, while other major players, including Lupin and Cipla, are also preparing to enter the market.

Currently, branded drugs like Ozempic cost over ₹2,200 per week for starter doses, making them unaffordable for many. Analysts predict that generics could reduce costs by 50–90 percent, bringing monthly expenses down to around ₹3,000–₹6,500, and possibly as low as ₹3,300 in the long term due to competition.

Experts call this a “magic pill moment” for India, where the number of people with diabetes and obesity continues to rise. 

Affordable GLP-1 receptor agonists like semaglutide can help manage blood sugar levels, support weight loss, and prevent long-term health complications.

Doctors caution, however, that ensuring quality and a smooth supply chain will be critical. Patients will also need proper guidance on usage, monitoring, and lifestyle changes to get the maximum benefit.

“Semaglutide generics have the potential to revolutionize diabetes and obesity treatment in India,” says Dr. Anjali Menon, endocrinologist at AIIMS Delhi. “This could improve access for millions while helping prevent serious health issues related to diabetes and weight gain.”